Jiangsu Hengrui Medicine Co., Ltd.

This study tests a new drug (HR070803) added to standard chemotherapy and a targeted therapy for people with advanced colorectal cancer that has spread and cannot be removed by surgery. About 669 participants will receive either the new combo or standard treatment. The goal is to…

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This study tests whether adding two drugs (camrelizumab and rivoceranib) to a standard procedure called TACE can help people with liver cancer that cannot be removed by surgery. The trial includes 423 adults with liver cancer who have not had prior treatment. The goal is to see i…

This study tests a new medication, SHR-3167, against a standard long-acting insulin (insulin degludec) in people with type 2 diabetes who already use basal insulin. The goal is to see which one controls blood sugar better and is safer. About 173 adults aged 18-65 with type 2 diab…

This phase 3 study tests whether a combination of two drugs (camrelizumab and famitinib) works better than standard chemotherapy for women with cervical cancer that has returned or spread. About 443 women who have not had prior treatment for advanced disease will be randomly assi…

This study tests a new drug called HRS-4642 combined with other anti-cancer medicines in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the combination is safe and helps shrink or control tumors. About 47 adults aged …

This study tests a new drug called SHR-A1811, given alone or with pertuzumab, against the standard treatment (trastuzumab, pertuzumab, and docetaxel) for women with HER2-positive breast cancer that has come back or spread. About 868 women aged 18 to 75 with measurable tumors and …

This study tests a new medicine called SHR-3167 in adults with type 2 diabetes whose blood sugar is not well controlled by pills. About 100 participants will receive different dosing plans to see which works best at lowering blood sugar while avoiding dangerously low sugar levels…

This early-stage study tests a new drug called HRS-3738 in people with two types of blood cancer—non-Hodgkin's lymphoma and multiple myeloma—that have returned or not improved after prior treatments. The main goals are to find a safe dose and check how well the drug works. About …